Active Ingredient History

NOW
  • Now
Liafensine (BMS-820836) is a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) which was under development by Bristol-Myers Squibb for the treatment of major depressive disorder. Though it demonstrated comparable effectiveness to escitalopram and duloxetine in phase II clinical trials, development was terminated in 2013 because liafensine failed to show superior effectiveness relative to these drugs, a decision that was made likely based on its increased capacity for side effects as well as potential for abuse.   Wikipedia

  • SMILES: CN1C[C@@H](c2ccc3ccccc3c2)c4ccc(cc4C1)c5ccc(N)nn5
  • InChIKey: VCIBGDSRPUOBOG-QFIPXVFZSA-N
  • Mol. Mass: 366.47
  • ALogP: 4.46
  • ChEMBL Molecule:
More Chemistry
6-(2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl)pyridazin-3-amine | bms-820836 | liafensine

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue